Patient : Mr. Sharadkumar (112385) PRN : 398627 IP No.

:­
Age/Sex : 33 Yrs/Male Visit No. : OP­1 Date : 23/03/2021
Referred By : Dr. CMO . Sample Collected : 23/03/2021 09:55
Location : OPD Sample Rcvd. in Lab : 23/03/2021 09:55
Sponsor : Excel Pathology Laboratory Reported On : 23/03/2021 13:35
Collected At : Terna Speciality Hospital And Research Centre Processed At : Terna Speciality Labs
Lab No. : 0012508221 Status : Verified

TERNA DIAGNOSTICS
(A Part of Terna Medical College)

Realtime qualitative RT­PCR detection of SARS­CoV2 (Covid 19)

Kit specification: TRUPCR, Screening –E gene, Confirmatory–RdRP& N gene, CT Cutoff<35

Specimen:Nasopharyngeal / Oropharyngeal
TARGET GENE DETECTED/NOT DETECTED CT VALUE

RdRp + N gene NOT DETECTED ­

ICMR Registration no.: ­ TDTMCHTMH

Result analysis
NOT DETECTED Results indicates absence of SARS CoV 2 RNA or less than detection limit in the
given sample

DETECTED Results indicate the presence of SARS CoV 2 RNA in the given sample

INCONCLUSIVE Target is inconclusive, Advised to send fresh specimen for recheck

Note

· A single negative test result, particularly if this is from an upper respiratory tract specimen,does not
exclude infection.
· Repeat sampling and testing of lower respiratory tract specimen is strongly recommended in severe or
progressive disease.
· The repeat specimen may be considered after a gap of 2­4 days the collection of first specimen for
additional testing if required. In case of negative results, it is also advised to rule out other respiratory
pathogens like Influenza A, Influenza B,Influenza A (H1N1), Human rhino virus, Human Adenovirus,
ParaInfluenza virus,RSV, Enterovirus, Mycoplasma Pneumonia. Other human corona virus (OC43,
NL63,229E, HKUL).
· ICMR recommended kits are used for reporting. All the specimen testing are notifiable to ICMR New
Delhi and IDSP, Maharashtra State for further surveillance.

Procedure: COVID19 detection based on Real time PCR technology, for the qualitative detection and differentiation
of lineage B­beta corona virus (B CoV) and severe acute respiratory syndrome corona virus (SARS­CoV­2) specific
RNA based on the amplification. In real time PCR the amplified product is detected via fluorescent dyes.

Page 1 of 2
 Patient : Mr. Sharadkumar (112385) PRN : 398627 IP No. :­
Age/Sex : 33 Yrs/Male Visit No. : OP­1 Date : 23/03/2021
Referred By : Dr. CMO . Sample Collected : 23/03/2021 09:55
Location : OPD Sample Rcvd. in Lab : 23/03/2021 09:55
Sponsor : Excel Pathology Laboratory Reported On : 23/03/2021 13:35
Collected At : Terna Speciality Hospital And Research Centre Processed At : Terna Speciality Labs
Lab No. : 0012508221 Status : Verified
Limitation of the assay
1. Presence of PCR inhibitors may interfere with PCR amplification.
2. Negative result does not rule out the possibility of infection. Presence of inhibitor, mutation & insufficient organism
RNA can influence the result and should not be as a sole basis for management of the disease.

Disclaimer
1. The intention of the test is for use in conjunction with clinical presentation and other laboratory makers.
2. Improper sample collection, handling, storage and transportation may result in false negative results.
3. Sensitivity of this test depends on the quality of the sample submitted for the testing.

This report has been prepared by Terna Diagnostics (A part of Terna Medical College).

­­­­­­­­­­­­­­­­End Of Report­­­­­­­­­­­­­­­­

Dr. Anila Prabil

M.D (Microbiologist)
Entered By:YOGESHB

Page 2 of 2